# Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

> **NCT04900818** · PHASE1 · RECRUITING · sponsor: **I-Mab Biopharma US Limited** · enrollment: 330 (estimated)

## Conditions studied

- Solid Tumor
- Advanced Cancer
- Metastatic Cancer
- Gastric Cancer
- Gastroesophageal Junction Carcinoma
- Esophageal Adenocarcinoma
- PDAC - Pancreatic Ductal Adenocarcinoma
- Biliary Tract Cancer (BTC)

## Interventions

- **DRUG:** TJ033721 (givastomig)
- **DRUG:** TJ033721 (givastomig) , nivolumab, chemotherapy
- **DRUG:** TJ033721 (givastomig), chemotherapy
- **DRUG:** TJ033721 (givastomig), durvalumab, chemotherapy

## Key facts

- **NCT ID:** NCT04900818
- **Lead sponsor:** I-Mab Biopharma US Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-06-29
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04900818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04900818, "Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT04900818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*